Top Recruiting Trials
20 actively recruiting studies
Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas
Institut Claudius Regaud
n=86
CHU Amiens
Amiens
Intervention DRUG: Pembrolizumab + Cisplatin/Carboplatin + 5-FU — * 4 cycles of combination treatment: 4 cycles of pembrolizumab (200 mg IV on Day 1 of each 3-week cycle) in combination ...
Eligibility Ages 18 Years
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Nimbus Wadjet, Inc.
n=134
USC Norris Comprehensive Cancer Center
Los Angeles, California
Intervention DRUG: NDI-219216 — NDI-219216 is a highly selective small molecule inhibitor of WRN helicase activity.
Eligibility Ages 18 Years – 99 Years
A Study of HDM2020 in Patients With Advanced Sq-NSCLC
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
n=150
Guangdong Provincial People's Hospital
Guangzhou, Guangdong
Intervention DRUG: HDM2020 (FGFR2b-ADC) — This Phase I study only focuses on squamous non-small cell lung cancer.
Eligibility Ages 18 Years – 75 Years
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
City of Hope Medical Center
n=1250
City of Hope Medical Center
Duarte, California
Intervention OTHER: Quality-of-Life Assessment — Complete quality of life questionnaire
Eligibility Ages 18 Years
Contact Christiane Querfeld · City of Hope Medical Center
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
Fudan University
n=83
Dongmei Ji
Shanghai, Shanghai Municipality
Intervention DRUG: R-CDOP+intrathecal MTX — R-CDOP+intrathecal MTX：
* Rituximab 375 mg / m\^2，D1
* Cyclophosphamide 750 mg / m\^2，D2
* Doxorubicin Hydrochloride Li...
Eligibility Ages 18 Years – 75 Years
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Daiichi Sankyo
n=540
Highlands Oncology Group
Springdale, Arkansas
Intervention DRUG: Ifinatamab deruxtecan — 12 mg/kg intravenous dose on Day 1 of each 21-day cycle
Eligibility Ages 18 Years
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
AbbVie
n=199
University of Southern California /ID# 272414
Los Angeles, California
Intervention DRUG: ABBV-453 — Oral Tablet
Eligibility Ages 18 Years
Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
Mayo Clinic
n=70
Mayo Clinic in Rochester
Rochester, Minnesota
Intervention OTHER: Best Practice — Receive standard of care
Eligibility Ages 18 Years
Social Optimization Study
University of Arizona
n=30
University of Arizona Mel and Enid Zuckerman College of Public Health
Tucson, Arizona
Intervention BEHAVIORAL: Social support receptivity training — A 3-week, 6-session CBT intervention that targets cognitive awareness of prosocial cues and leverages behavioral activat...
Eligibility Ages 18 Years – 99 Years
Sensitivity of Organoids to Predict Treatment Outcome in Breast Cancer Metastases
King's College London
n=20
Guy's and St. Thomas NHS Foundation Trust
London
Eligibility Ages 18 Years
Comprehensive Geriatric Assessment (Tests) for Bladder Cancer Participants Undergoing Radical Cystectomy
University of Chicago
n=85
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois
Intervention OTHER: Educational Video Modules on Risk Prevention Before and After Cystectomy (Surgery) — An educational program designed by geriatricians, surgeons, anesthesiologists and palliative care physicians to help peo...
Eligibility Ages 65 Years
Mepitel Film Breast
National University Hospital, Singapore
n=60
National University Hospital
Singapore
Eligibility Ages 21 Years – 100 Years
BAI-BACE for Advanced Lung Squamous Cell Carcinoma
Sun Yat-sen University
n=85
Chinese PLA General hospital
Beijing, Beijing Municipality
Intervention PROCEDURE: BAI-BACE — Bronchial arterial infusion, bronchial arterial chemoembolization (BACE-BAI) procedure was performed as follows: Bronchi...
Eligibility Ages 18 Years – 80 Years
PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER
Banner Health
n=30
Banner MD Anderson Cancer Center
Gilbert, Arizona
Intervention PROCEDURE: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy — CRS/HIPEC involves aggressive surgical cytoreduction of all visible and palpable tumors, followed by the synergistic use...
Eligibility Ages 18 Years
ULTRA-LAP Trial: Laparoscopic Debulking Surgery (LDS) in Advanced Ovarian Cancer
Azienda Ospedaliera di Padova
n=62
Azienda Ospedaliera Universitaria di Padova,
Padova, Padova, Veneto
Intervention PROCEDURE: Laparoscopic Debulking Surgery in advanced ovarian cancer — Laparoscopic debulking will be conducted until the surgical target is achieved or the operation is converted to laparoto...
Eligibility Ages 18 Years, FEMALE only
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
TuHURA Biosciences, Inc.
n=9
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Intervention DRUG: IFx-Hu2.0 — Therapeutic Classification:
• Innate immune agonist
Route of Administration:
• Intralesional
Eligibility Ages 18 Years
A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood
Second Affiliated Hospital, Zhejiang University, School of Medicine
n=104
The Second Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang
Intervention DRUG: Sintilimab — Sintilimab is administered intravenously on the first day of each cycle. 21 days per cycle.
Eligibility Ages 18 Years – 75 Years
Buddy-Up Dyadic Physical Activity Program for Persons With Dementia and Family Caregivers
The University of Hong Kong
n=236
The University of Hong Kong
Hong Kong
Intervention OTHER: Buddy-Up Dyadic Physical Activity (BUDPA) program — BUDPA program is an overall 16-week training which comprises three phases: the conditioning, consolidating and habituati...
Eligibility Ages 18 Years
A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors
Philogen S.p.A.
n=56
ASST Papa Giovanni XXIII Piazza OMS
Bergamo, Bergamo
Intervention DRUG: [177Lu]Lu-OncoFAP-23 — 3.7, 7.4, or 11.1 GBq to define the RD
Eligibility Ages 18 Years
Emotional Awareness and Communication Training Effectiveness in Oncology Nurses
Ankara Yildirim Beyazıt University
n=64
Ankara Etlik City Hospital
Ankara, Yenimahalle
Intervention BEHAVIORAL: Structured Emotional Awareness and Communication Training — Participants in the intervention group will receive a structured training program over four weeks, consisting of weekly ...
Eligibility Ages 18 Years